Implementing and delivering a successful biosimilar switch programme - the Berkshire West experience.

Background And Aims: Biosimilars used in multiple rheumatic conditions offer the -potential for cost savings. We present the outcomes of a -service evaluation of switching rheumatic patients established on originator etanercept (Enbrel) to biosimilar Benepali, using a managed switching programme funded through a novel fixed price incentivisation model.

Methods: Evaluation outcomes included savings in drug acquisition costs, patient-reported side effects, adverse events, patient outcomes and patient experience.